Pre-biologic Panel

A growing need for biologic therapy

In the US, conditions treated with biologics are on the rise, from rheumatoid arthritis to inflammatory bowel disease.1,2

Treating with some biologics can suppress the immune system, making those patients undergoing treatment more susceptible to infection.3 That’s why screening for latent infections like tuberculosis (TB) and other infections like hepatitis is recommended by a number of leading health organizations.4,5

Biologics-treated conditions on the rise in the US:

6 million have plaque psoriasis6
1.6 million have inflammatory bowel disease2
1.5 million have rheumatoid arthritis7

Preparing for biologic therapy: recommended screening

Biologic agents are currently used for the treatment of rheumatoid arthritis, plaque psoriasis, and inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, among other autoimmune diseases.

For patients with these conditions who are starting or currently receiving certain biologic agents, the American Academy of Dermatology (AAD), American College of Rheumatology (ACR) and American College of Gastroenterology (ACG) recommend screening for hepatitis B (HBV), hepatitis C (HCV) and latent TB infection. 4,5,8,9

Detect infection with the Pre-biologic Panel

Available exclusively from Quest Diagnostics, the Pre-biologic Panel includes the ACR and ACG guideline-recommended tests you need to evaluate your patients for biologic or biosimilar therapy.

Additional testing may need to be considered. The treating healthcare professional should refer to the manufacturer’s approved labeling for prescribing, warnings, side effects and other important information.

  • HBV screening
  • HCV screening
  • TB infection screening (interferon gamma release assay or IGRA)
Test Name Test Code Test Components
Pre-biologic/biosimilar Screen Panel, HCV/HBV with Reflexes and QFT 1 Tube* 37616

Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LiPA®

Hepatitis B Surface Antigen with Reflex Confirmation

Hepatitis B Surface Antibody Immunity, Quantitative

Hepatitis B Core Antibody, Total, with Reflex to IgM

QuantiFERON®-TB Gold Plus (1-tube)

Pre-biologic/biosimilar Screen Panel, HCV/HBV with Reflexes and QFT 4 Tubes* 37620

Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LiPA®

Hepatitis B Surface Antigen with Reflex Confirmation

Hepatitis B Surface Antibody Immunity, Quantitative

Hepatitis B Core Antibody, Total, with Reflex to IgM

QuantiFERON®-TB Gold Plus (4-tube)

*Panel components may be ordered separately.

Help ensure compliance and clear the way for patient therapy

Download the Pre-biologic Panel sell sheet
Contact a Quest sales representative
  1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25.
  2. Crohn’s & Colitis Foundation of America. The facts about inflammatory bowel diseases. November 2014. Available at http://www.crohnscolitisfoundation.org/assets/pdfs/updatedibdfactbook.pdf. Accessed March 8, 2019.
  3. Kane SV. Preparing for biologic or immunosuppressant therapy. Gastroenterol Hepatol. 2011;7(8):544-546.
  4. American College of Rheumatology. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625-639.
  5. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241-258.
  6. National Psoriasis Foundation. Statistics. https://www.psoriasis.org/content/statistics. Accessed March 8, 2019.
  7. Arthritis Foundation. Arthritis by the numbers: book of trusted facts & figures. 2018;2:8. https://www.arthritis.org/Documents/Sections/About-Arthritis/arthritis-facts-stats-figures.pdf. Accessed March 14, 2019.
  8. Chebli JMF, Gaburri PD, Chebli LA, et al. A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit. 2014;20:487-498.
  9. Menter, A, et al. Joint ADD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Biologics. J Am Acad Dermatol. April 2019; 1029-1072.